Foghorn Therapeutics Inc.
FHTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $259 | $271 | $265 | $850 |
| - Cash | $55 | $80 | $346 | $101 |
| + Debt | $37 | $45 | $52 | $58 |
| Enterprise Value | $241 | $235 | -$29 | $807 |
| Revenue | $23 | $34 | $19 | $1 |
| % Growth | -33.8% | 77.6% | 1,357.8% | – |
| Gross Profit | $23 | $34 | $19 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$97 | -$104 | -$114 | -$96 |
| % Margin | -429.9% | -305.8% | -591.9% | -7,292.4% |
| Net Income | -$87 | -$98 | -$109 | -$101 |
| % Margin | -383.2% | -288.2% | -566.3% | -7,681.6% |
| EPS Diluted | -1.58 | -2.34 | -2.62 | -2.78 |
| % Growth | 32.5% | 10.7% | 5.8% | – |
| Operating Cash Flow | -$100 | -$118 | $194 | -$50 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$3 |
| Free Cash Flow | -$101 | -$119 | $192 | -$54 |